Skip to main content
Top
Published in: Clinical and Experimental Medicine 4/2016

01-11-2016 | Original Article

Increased inflammatory markers with altered antioxidant status persist after clinical recovery from severe sepsis: a correlation with low HDL cholesterol and albumin

Authors: Lucie Vavrova, Jana Rychlikova, Magdalena Mrackova, Olga Novakova, Ales Zak, Frantisek Novak

Published in: Clinical and Experimental Medicine | Issue 4/2016

Login to get access

Abstract

Markers of oxidative stress and antioxidant status in relation to inflammatory mediators in septic patients (SPs) during the course of sepsis and after recovery were analysed. Patients were 30 critically ill adults in severe sepsis/septic shock, 19 of which completed 3 samplings (S1: within 24 h after onset of sepsis, S7: 7 days after S1, R7: 7 days after clinical recovery). Comparing SPs with healthy controls (HCs), enhanced C-reactive protein, procalcitonin, bilirubin and CuZn-superoxide dismutase activity were found at S1 only. Oxidized low-density lipoprotein, conjugated dienes and nitrotyrosine were increased at S1, culminated at S7 and reverted nearly to HC levels at R7. Reduced catalase activity and serum amyloid were observed at S1 and endured until R7. Increase in IL-6, IL-10 and tumour necrosis factor alpha (TNF-α) with accompanying decrease in apolipoprotein A1, high-density lipoprotein (HDL) cholesterol, selenium, zinc, albumin, paraoxonase 1 and glutathione peroxidase 1 activity appeared at S1 and persisted until R7. TNF-α, IL-10 and markers of oxidative stress were in negative correlation with HDL cholesterol and albumin at R7. After clinical recovery, increased cytokines and decreased antioxidants were accompanied by lower albumin and HDL cholesterol levels. During this important and beneficial period of tissue repair, patients with prolonged persistence of this status are probably more vulnerable to secondary infections and should be dealt with as constituting a high-risk population.
Literature
1.
go back to reference Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003;31:1250–6.PubMedCrossRef Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003;31:1250–6.PubMedCrossRef
2.
go back to reference Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10.PubMedCrossRef Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10.PubMedCrossRef
3.
go back to reference van Ruler O, Schultz MJ, Reitsma JB, Gouma DJ, Boermeester MA. Has mortality from sepsis improved and what to expect from new treatment modalities: review of current insights. Surg Infect (Larchmt). 2009;10:339–48.CrossRef van Ruler O, Schultz MJ, Reitsma JB, Gouma DJ, Boermeester MA. Has mortality from sepsis improved and what to expect from new treatment modalities: review of current insights. Surg Infect (Larchmt). 2009;10:339–48.CrossRef
5.
go back to reference Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138–50.PubMedCrossRef Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138–50.PubMedCrossRef
6.
go back to reference Gullo A, Bianco N, Berlot G. Management of severe sepsis and septic shock: challenges and recommendations. Crit Care Clin. 2006;22:489–501.PubMedCrossRef Gullo A, Bianco N, Berlot G. Management of severe sepsis and septic shock: challenges and recommendations. Crit Care Clin. 2006;22:489–501.PubMedCrossRef
8.
go back to reference Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008;29:617–25.PubMedPubMedCentralCrossRef Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008;29:617–25.PubMedPubMedCentralCrossRef
9.
go back to reference Crimi E, Sica V, Williams-Ignarro S, et al. The role of oxidative stress in adult critical care. Free Radic Biol Med. 2006;40:398–406.PubMedCrossRef Crimi E, Sica V, Williams-Ignarro S, et al. The role of oxidative stress in adult critical care. Free Radic Biol Med. 2006;40:398–406.PubMedCrossRef
10.
go back to reference Goode HF, Cowley HC, Walker BE, Howdle PD, Webster NR. Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction. Crit Care Med. 1995;23:646–51.PubMedCrossRef Goode HF, Cowley HC, Walker BE, Howdle PD, Webster NR. Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction. Crit Care Med. 1995;23:646–51.PubMedCrossRef
11.
12.
go back to reference Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167:1655–63.PubMedPubMedCentralCrossRef Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167:1655–63.PubMedPubMedCentralCrossRef
13.
go back to reference Linner A, Sunden-Cullberg J, Johansson L, Hjelmqvist H, Norrby-Teglund A, Treutiger CJ. Short- and long-term mortality in severe sepsis/septic shock in a setting with low antibiotic resistance: a prospective observational study in a Swedish university hospital. Front Public Health. 2013;1:51.PubMedPubMedCentralCrossRef Linner A, Sunden-Cullberg J, Johansson L, Hjelmqvist H, Norrby-Teglund A, Treutiger CJ. Short- and long-term mortality in severe sepsis/septic shock in a setting with low antibiotic resistance: a prospective observational study in a Swedish university hospital. Front Public Health. 2013;1:51.PubMedPubMedCentralCrossRef
14.
go back to reference Lichtenstern C, Brenner T, Bardenheuer HJ, Weigand MA. Predictors of survival in sepsis: what is the best inflammatory marker to measure? Curr Opin Infect Dis. 2012;25:328–36.PubMedCrossRef Lichtenstern C, Brenner T, Bardenheuer HJ, Weigand MA. Predictors of survival in sepsis: what is the best inflammatory marker to measure? Curr Opin Infect Dis. 2012;25:328–36.PubMedCrossRef
15.
go back to reference Yende S, D’Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008;177:1242–7.PubMedPubMedCentralCrossRef Yende S, D’Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008;177:1242–7.PubMedPubMedCentralCrossRef
16.
go back to reference Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296–327.PubMedCrossRef Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296–327.PubMedCrossRef
17.
go back to reference Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286:1754–8.PubMedCrossRef Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286:1754–8.PubMedCrossRef
18.
go back to reference Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35:1126–38.PubMedPubMedCentral Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35:1126–38.PubMedPubMedCentral
19.
go back to reference Kodydkova J, Vavrova L, Zeman M, et al. Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem. 2009;42:1368–74.PubMedCrossRef Kodydkova J, Vavrova L, Zeman M, et al. Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem. 2009;42:1368–74.PubMedCrossRef
20.
go back to reference Ahotupa M, Ruutu M, Mantyla E. Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin Biochem. 1996;29:139–44.PubMedCrossRef Ahotupa M, Ruutu M, Mantyla E. Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin Biochem. 1996;29:139–44.PubMedCrossRef
21.
go back to reference Guevara I, Iwanejko J, Dembinska-Kiec A, et al. Determination of nitrite/nitrate in human biological material by the simple Griess reaction. Clin Chim Acta. 1998;274:177–88.PubMedCrossRef Guevara I, Iwanejko J, Dembinska-Kiec A, et al. Determination of nitrite/nitrate in human biological material by the simple Griess reaction. Clin Chim Acta. 1998;274:177–88.PubMedCrossRef
22.
go back to reference Lasanianos NG, Kanakaris NK, Dimitriou R, Pape HC, Giannoudis PV. Second hit phenomenon: existing evidence of clinical implications. Injury. 2011;42:617–29.PubMedCrossRef Lasanianos NG, Kanakaris NK, Dimitriou R, Pape HC, Giannoudis PV. Second hit phenomenon: existing evidence of clinical implications. Injury. 2011;42:617–29.PubMedCrossRef
23.
go back to reference Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000;181:176–80.PubMedCrossRef Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000;181:176–80.PubMedCrossRef
24.
go back to reference Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med. 1999;27:1262–4.PubMedCrossRef Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med. 1999;27:1262–4.PubMedCrossRef
25.
go back to reference Sethu S, Melendez AJ. New developments on the TNFalpha-mediated signalling pathways. Biosci Rep. 2011;31:63–76.PubMedCrossRef Sethu S, Melendez AJ. New developments on the TNFalpha-mediated signalling pathways. Biosci Rep. 2011;31:63–76.PubMedCrossRef
26.
go back to reference Huang ZF, Massey JB, Via DP. Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) in human in vitro differentiated macrophages. Biochem Pharmacol. 2000;59:187–94.PubMedCrossRef Huang ZF, Massey JB, Via DP. Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) in human in vitro differentiated macrophages. Biochem Pharmacol. 2000;59:187–94.PubMedCrossRef
28.
go back to reference Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother. 2011;66(Suppl 2):33–40. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother. 2011;66(Suppl 2):33–40.
29.
go back to reference Behnes M, Brueckmann M, Liebe V, et al. Levels of oxidized low-density lipoproteins are increased in patients with severe sepsis. J Crit Care. 2008;23:537–41.PubMedCrossRef Behnes M, Brueckmann M, Liebe V, et al. Levels of oxidized low-density lipoproteins are increased in patients with severe sepsis. J Crit Care. 2008;23:537–41.PubMedCrossRef
30.
go back to reference Baron P, Traber LD, Traber DL, et al. Gut failure and translocation following burn and sepsis. J Surg Res. 1994;57:197–204.PubMedCrossRef Baron P, Traber LD, Traber DL, et al. Gut failure and translocation following burn and sepsis. J Surg Res. 1994;57:197–204.PubMedCrossRef
31.
go back to reference Andresen M, Regueira T, Bruhn A, et al. Lipoperoxidation and protein oxidative damage exhibit different kinetics during septic shock. Mediators Inflamm. 2008;2008:168652.PubMedPubMedCentralCrossRef Andresen M, Regueira T, Bruhn A, et al. Lipoperoxidation and protein oxidative damage exhibit different kinetics during septic shock. Mediators Inflamm. 2008;2008:168652.PubMedPubMedCentralCrossRef
32.
go back to reference Strand OA, Leone A, Giercksky KE, Kirkeboen KA. Nitric oxide indices in human septic shock. Crit Care Med. 2000;28:2779–85.PubMedCrossRef Strand OA, Leone A, Giercksky KE, Kirkeboen KA. Nitric oxide indices in human septic shock. Crit Care Med. 2000;28:2779–85.PubMedCrossRef
33.
go back to reference Warner A, Bencosme A, Healy D, Verme C. Prognostic role of antioxidant enzymes in sepsis: preliminary assessment. Clin Chem. 1995;41:867–71.PubMed Warner A, Bencosme A, Healy D, Verme C. Prognostic role of antioxidant enzymes in sepsis: preliminary assessment. Clin Chem. 1995;41:867–71.PubMed
34.
go back to reference Cherian S, Jameson S, Rajarajeswari C, et al. Oxidative stress in sepsis in children. Indian J Med Res. 2007;125:143–8.PubMed Cherian S, Jameson S, Rajarajeswari C, et al. Oxidative stress in sepsis in children. Indian J Med Res. 2007;125:143–8.PubMed
35.
go back to reference Halliwell B, Gutteridge JMC. Free radicals in biology and medicine, 4th edn. New York: Oxford University Press Inc.; 2007. p. 123–124, 347–348. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine, 4th edn. New York: Oxford University Press Inc.; 2007. p. 123–124, 347–348.
36.
go back to reference Taylor DE, Piantadosi CA. Oxidative metabolism in sepsis and sepsis syndrome. J Crit Care. 1995;10:122–35.PubMedCrossRef Taylor DE, Piantadosi CA. Oxidative metabolism in sepsis and sepsis syndrome. J Crit Care. 1995;10:122–35.PubMedCrossRef
38.
go back to reference Leff JA, Parsons PE, Day CE, et al. Increased serum catalase activity in septic patients with the adult respiratory distress syndrome. Am Rev Respir Dis. 1992;146:985–9.PubMedCrossRef Leff JA, Parsons PE, Day CE, et al. Increased serum catalase activity in septic patients with the adult respiratory distress syndrome. Am Rev Respir Dis. 1992;146:985–9.PubMedCrossRef
39.
go back to reference Andersen HR, Nielsen JB, Nielsen F, Grandjean P. Antioxidative enzyme activities in human erythrocytes. Clin Chem. 1997;43:562–8.PubMed Andersen HR, Nielsen JB, Nielsen F, Grandjean P. Antioxidative enzyme activities in human erythrocytes. Clin Chem. 1997;43:562–8.PubMed
40.
go back to reference Ding L, Liu Z, Zhu Z, Luo G, Zhao D, Ni J. Biochemical characterization of selenium-containing catalytic antibody as a cytosolic glutathione peroxidase mimic. Biochem J. 1998;332(Pt 1):251–5.PubMedPubMedCentralCrossRef Ding L, Liu Z, Zhu Z, Luo G, Zhao D, Ni J. Biochemical characterization of selenium-containing catalytic antibody as a cytosolic glutathione peroxidase mimic. Biochem J. 1998;332(Pt 1):251–5.PubMedPubMedCentralCrossRef
41.
go back to reference Forceville X, Vitoux D, Gauzit R, Combes A, Lahilaire P, Chappuis P. Selenium, systemic immune response syndrome, sepsis, and outcome in critically ill patients. Crit Care Med. 1998;26:1536–44.PubMedCrossRef Forceville X, Vitoux D, Gauzit R, Combes A, Lahilaire P, Chappuis P. Selenium, systemic immune response syndrome, sepsis, and outcome in critically ill patients. Crit Care Med. 1998;26:1536–44.PubMedCrossRef
42.
go back to reference Mills GC. Hemoglobin catabolism. I. Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown. J Biol Chem. 1957;229:189–97.PubMed Mills GC. Hemoglobin catabolism. I. Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown. J Biol Chem. 1957;229:189–97.PubMed
43.
go back to reference Ogilvie AC, Groeneveld AB, Straub JP, Thijs LG. Plasma lipid peroxides and antioxidants in human septic shock. Intensive Care Med. 1991;17:40–4.PubMedCrossRef Ogilvie AC, Groeneveld AB, Straub JP, Thijs LG. Plasma lipid peroxides and antioxidants in human septic shock. Intensive Care Med. 1991;17:40–4.PubMedCrossRef
44.
go back to reference Weber SU, Lehmann LE, Schewe JC, et al. Low serum alpha-tocopherol and selenium are associated with accelerated apoptosis in severe sepsis. BioFactors. 2008;33:107–19.PubMedCrossRef Weber SU, Lehmann LE, Schewe JC, et al. Low serum alpha-tocopherol and selenium are associated with accelerated apoptosis in severe sepsis. BioFactors. 2008;33:107–19.PubMedCrossRef
46.
go back to reference Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg. 1999;134:36–42.PubMedCrossRef Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg. 1999;134:36–42.PubMedCrossRef
47.
go back to reference Kragh-Hansen U, Minchiotti L, Galliano M, Peters T Jr. Human serum albumin isoforms: genetic and molecular aspects and functional consequences. Biochim Biophys Acta. 2013;1830:5405–17.PubMedCrossRef Kragh-Hansen U, Minchiotti L, Galliano M, Peters T Jr. Human serum albumin isoforms: genetic and molecular aspects and functional consequences. Biochim Biophys Acta. 2013;1830:5405–17.PubMedCrossRef
48.
go back to reference Evans TW. Review article: albumin as a drug–biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther. 2002;16(Suppl 5):6–11.PubMedCrossRef Evans TW. Review article: albumin as a drug–biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther. 2002;16(Suppl 5):6–11.PubMedCrossRef
49.
go back to reference Chiarla C, Giovannini I, Giuliante F, et al. Severe hypocholesterolemia in surgical patients, sepsis, and critical illness. J Crit Care. 2010;25:361.PubMedCrossRef Chiarla C, Giovannini I, Giuliante F, et al. Severe hypocholesterolemia in surgical patients, sepsis, and critical illness. J Crit Care. 2010;25:361.PubMedCrossRef
50.
go back to reference van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med. 2003;31:1359–66.PubMedCrossRef van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med. 2003;31:1359–66.PubMedCrossRef
51.
go back to reference Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond). 2009;116:87–98.PubMedCrossRef Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond). 2009;116:87–98.PubMedCrossRef
52.
go back to reference Gordon BR, Parker TS, Levine DM, et al. Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med. 2001;29:1563–8.PubMedCrossRef Gordon BR, Parker TS, Levine DM, et al. Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med. 2001;29:1563–8.PubMedCrossRef
53.
go back to reference Luthold S, Berneis K, Bady P, Muller B. Effects of infectious disease on plasma lipids and their diagnostic significance in critical illness. Eur J Clin Invest. 2007;37:573–9.PubMedCrossRef Luthold S, Berneis K, Bady P, Muller B. Effects of infectious disease on plasma lipids and their diagnostic significance in critical illness. Eur J Clin Invest. 2007;37:573–9.PubMedCrossRef
54.
go back to reference Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.PubMedCrossRef Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.PubMedCrossRef
55.
go back to reference Marsche G, Saemann MD, Heinemann A, Holzer M. Inflammation alters HDL composition and function: implications for HDL-raising therapies. Pharmacol Ther. 2013;137:341–51.PubMedCrossRef Marsche G, Saemann MD, Heinemann A, Holzer M. Inflammation alters HDL composition and function: implications for HDL-raising therapies. Pharmacol Ther. 2013;137:341–51.PubMedCrossRef
56.
go back to reference Mackness B, Hine D, McElduff P, Mackness M. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis. 2006;186:396–401.PubMedCrossRef Mackness B, Hine D, McElduff P, Mackness M. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis. 2006;186:396–401.PubMedCrossRef
57.
go back to reference Precourt LP, Amre D, Denis MC, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis. 2011;214:20–36.PubMedCrossRef Precourt LP, Amre D, Denis MC, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis. 2011;214:20–36.PubMedCrossRef
58.
go back to reference Novak F, Vavrova L, Kodydkova J, et al. Decreased paraoxonase activity in critically ill patients with sepsis. Clin Exp Med. 2010;10:21–5.PubMedCrossRef Novak F, Vavrova L, Kodydkova J, et al. Decreased paraoxonase activity in critically ill patients with sepsis. Clin Exp Med. 2010;10:21–5.PubMedCrossRef
59.
60.
go back to reference Draganov D, Teiber J, Watson C, et al. PON1 and oxidative stress in human sepsis and an animal model of sepsis. Adv Exp Med Biol. 2010;660:89–97.PubMedCrossRef Draganov D, Teiber J, Watson C, et al. PON1 and oxidative stress in human sepsis and an animal model of sepsis. Adv Exp Med Biol. 2010;660:89–97.PubMedCrossRef
61.
go back to reference Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26:892–904.PubMedCrossRef Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26:892–904.PubMedCrossRef
62.
go back to reference Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem. 1998;273:6088–95.PubMedCrossRef Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem. 1998;273:6088–95.PubMedCrossRef
63.
go back to reference James RW, Deakin SP. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med. 2004;37:1986–94.PubMedCrossRef James RW, Deakin SP. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med. 2004;37:1986–94.PubMedCrossRef
64.
65.
go back to reference Sammalkorpi K, Valtonen V, Kerttula Y, Nikkila E, Taskinen MR. Changes in serum lipoprotein pattern induced by acute infections. Metabolism. 1988;37:859–65.PubMedCrossRef Sammalkorpi K, Valtonen V, Kerttula Y, Nikkila E, Taskinen MR. Changes in serum lipoprotein pattern induced by acute infections. Metabolism. 1988;37:859–65.PubMedCrossRef
66.
Metadata
Title
Increased inflammatory markers with altered antioxidant status persist after clinical recovery from severe sepsis: a correlation with low HDL cholesterol and albumin
Authors
Lucie Vavrova
Jana Rychlikova
Magdalena Mrackova
Olga Novakova
Ales Zak
Frantisek Novak
Publication date
01-11-2016
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 4/2016
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-015-0390-1

Other articles of this Issue 4/2016

Clinical and Experimental Medicine 4/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.